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ABSTRACT
Introduction: To investigate the efficacy of a
treatment strategy with latanoprost and
dorzolamide in primary pediatric glaucoma
patients partially responsive to surgery.
Methods: Single arm, prospective,
interventional multicenter study. Primary
pediatric glaucoma patients younger than
13 years after a single surgical procedure with
IOP between 22 and 26 mmHg were considered
eligible. At baseline, patients were allocated to
latanoprost monotherapy once daily.
Depending on intraocular pressure (IOP)
reduction at first visit, the patients were
allocated to one of three groups: continuation
of latanoprost monotherapy, addition of
dorzolamide twice daily, or switch to
dorzolamide three times daily. The same
approach for allocation in medication groups
was used in all subsequent visits. Patients in the
dorzolamide monotherapy group with IOP
reduction\20% from baseline were considered
non-responders and withdrawn. Study
treatment and patient follow-up will continue
for 3 years or until treatment failure. The
primary endpoint is the percentage of
responders. Secondary endpoints are time to
treatment failure and frequency of adverse
events.
Results: A total of 37 patients (69 eyes) were
enrolled. The mean age was 4.0 ± 3.8 years, the
female/male ratio was 1/1.7, and the majority of
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patients were Caucasian. Eighty percent of
patients had bilateral glaucoma. Goniotomy
was the most frequently performed surgery
(38.6%), followed by trabeculotomy (22.8%),
trabeculectomy (21.1%), and trabeculectomy
plus trabeculotomy (17.5%). The baseline IOP
was 23.6 ± 1.5 mmHg.
Conclusion: The study population is
representative of patients frequently
encountered after the first surgery for primary
pediatric glaucoma. The study will produce
evidence on the medium-term efficacy of a
defined pharmacological approach.
Keywords: Dorzolamide; Latanoprost; Medical
therapy; Ophthalmology; Pediatric glaucoma;
Surgery
INTRODUCTION
Pediatric glaucoma represents a group of
potentially blinding diseases characterized by
elevated intraocular pressure (IOP). The
prognosis is largely dependent on early,
accurate diagnosis and successful treatment
that lowers IOP to levels where progression is
unlikely [1]. Due to the rarity of these
glaucomas, epidemiologic and prospective
randomized studies are difficult to undertake.
According to the latest classification
proposed by the World Glaucoma Association
Consensus group, pediatric glaucoma is
classified as primary or secondary [2]. In this
classification, the term primary refers to
glaucomas caused by anomaly of filtration
angle, while secondary pediatric glaucoma is
further classified according to whether the
disease is acquired after birth or is present at
birth (non-acquired). Non-acquired pediatric
glaucoma is categorized according to whether
the signs are mainly ocular or systemic.
Although surgery is the definitive treatment
of choice for patients with pediatric glaucoma
[3–11], topical medications are usually also
needed as temporary treatment before surgery
or as adjunctive postoperative therapy [12, 13].
Beta blockers, carbonic anhydrase inhibitors
(CAIs) and prostaglandins have all been used
in the treatment of pediatric glaucomas [14–16].
Raber and colleagues reported on the safety of
latanoprost exposure in a phase 1 study in
pediatric and adult glaucoma patients [17]. The
systemic exposure to latanoprost acid appeared
higher in children than in adults, and suggested
that this was due to lower body weight and a
small blood volume in children [17]. This
higher systemic exposure in children was not
accompanied by adverse events, and thus there
was an adequate safety margin for the use of an
adult topical dose of latanoprost in children
[17]. In a 12-week study, with pediatric
glaucoma patients, latanoprost and 0.5%
timolol were found to have similar efficacy
and tolerability. Mean IOP reductions for
latanoprost and timolol after 12 weeks were
7.2 and 5.7 mmHg, respectively. However,
responder rates (subjects with IOP reduction of
at least 15%) appeared to be low (60% for
latanoprost and 52% for timolol) [18].
Latanoprost and dorzolamide are commonly
used in pediatric glaucoma patients due to their
favorable efficacy and safety profile
[14–17, 19–22]. At present, no data are
available from prospective clinical trials on the
efficacy and safety of a defined therapeutic
strategy for the treatment of primary pediatric
glaucoma (PPG). The Glaucoma Italian Pediatric
Study (GIPSy) investigated the use of a specific
therapeutic algorithm with latanoprost and
dorzolamide in pediatric glaucoma patients
partially responsive to surgery. This article
reports the study protocol and baseline
characteristics of study participants.
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METHODS
Study Objective and Design
The GIPSy is a single arm, prospective,
interventional study evaluating the IOP
lowering effect of latanoprost and dorzolamide
in PPG partially responsive to surgery.
Study Organization
Patient recruitment was performed in two
institutions in Italy: Dipartimento di Scienze
Neurologiche e della Visione, USVD ‘‘Centro per
lo studio del Glaucoma’’, A.O ‘‘Spedali Civili di
Brescia’’ in Brescia and U.O. Oculistica, A.O.
Universitaria, ‘‘Policlinico Vittorio Emanuele’’,
P.O. Gaspare Rodolico in Catania. The study
was conducted in accordance with the
Declaration of Helsinki of 1964 as revised in
2013. The study protocol was approved by the
Institutional Review Board of each centre.
Parents provided written informed consent
prior to any study-related activities. The
investigation was registered with
clinicaltrials.gov (NCT01527682) and was
supported by a grant from the Italian
Medicines Agency (AIFA – FARM7CZ54W 2007).
Patient Eligibility Criteria
Eligible patients were younger than 13 years
with unilateral or bilateral PPG and IOP levels
between 22 and 26 mmHg following a single
surgical procedure. PPG was defined by the
presence of two or more of the following
criteria: IOP[21 mm Hg, optic disc cupping
(neuroretinal rim narrowing); corneal findings:
Haab striae, corneal edema or diameter C11 in
newborn, [12 mm in child\1 year of
age,[13 mm any age; progressive myopia or
myopic shift coupled with an increase in ocular
dimensions out of keeping with normal growth;
and a reproducible visual field defect that is
consistent with glaucomatous optic neuropathy
with no other observable reason for visual field
defect [23].
Children with secondary glaucoma
(Sturge–Weber syndrome, type I
neurofibromatosis, retinoblastoma,
steroid-induced glaucoma, etc.), or with
abnormalities of the anterior segment of the
eye (cataract, iridocorneal dysgenesis,
congenital ectropion uveae, etc.) or children
previously treated with the study drugs were not
eligible. Children with concomitant systemic
diseases (asthma, hypertension, cardiac disease,
renal failure, etc.) requiring pharmacological
treatment with IOP-modifying drugs (i.e.,
corticosteroids, beta-blockers, diuretics) or
with corneal abnormalities that could
influence IOP readings were excluded from the
study.
The following operations were allowed in the
study: goniotomy, trabeculotomy,
trabeculectomy with adjunctive mitomycin C,
and trabeculectomy plus trabeculotomy with
adjunctive mitomycin C. Study treatment was
to be initiated at least 1 month after surgery.
Topical steroids were stopped 1–2 weeks
post-operatively following goniotomy and
trabeculotomy, and continued 4 times a day
for 3 months following trabeculectomy and
trabeculectomy plus trabeculotomy with
adjunctive mitomycin C. All necessary
maneuvers (massage, remove or loosen
sutures, conjunctival bleb needling) were
performed before enrolling patients for the trial.
Procedures
Eligible patients had a baseline clinical
evaluation that included IOP measurement
[sitting position: Goldmann applanation
tonometer (Haag-Streit, Bern, Switzerland);
supine position: Perkins applanation
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tonometer (Clement Clarke MK2, Harlow,
England)], central corneal thickness (CCT)
measurement with ultrasound pachymeter
(DGH 500, PachetteTM; DGH Technology,
Exton, USA), anterior segment photography
for eyelash growth and iris color, and optic
disc photography. Two experienced examiners
performed all IOP measurements. Tonometry
was performed in the supine position under
general anesthesia in non-collaborative
children. General anesthesia was obtained by
small dose of ketamine and IOP was measured
as soon as possible after aesthesia induction
[24]. The exact time of IOP measurement was
recorded. These examinations were repeated in
all subsequent study visits. At the end of the
baseline visit patients were prescribed branded
latanoprost 0.005% eye drops (Xalatan 0.005%
eye drops solution; Pfizer Italia) to be instilled
once daily at bedtime (2100 hours). The parents
of enrolled children were instructed on the
appropriate technique of eye-drop
administration. The importance of timely
instillation of eye-drops followed by eyelid
closure and punctual occlusion was stressed.
The first study visit was performed
approximately 30 days after commencement of
treatment. IOP was measured at the same hour
as the baseline visit. If IOP decreased by C20%
with respect to baseline, the patient was
instructed to continue treatment with
latanoprost alone. In cases with IOP decrease
between 10 and 19% from baseline, branded
dorzolamide 2% ophthalmic solution (Trusopt
2% eye drops solution; MSD Italia) twice a day
(0800 and 2000 hours) was added to latanoprost
(2100 hours). Finally, in cases with IOP
decrease\10% from baseline or in cases with
IOP elevation, treatment with latanoprost was
discontinued and dorzolamide 2% ophthalmic
solution was prescribed three times daily (0800,
1400 and 2000 hours).
The second study visit was performed
60 days after the baseline visit. If the IOP
decrease was major or equal to 20% with
respect to baseline, treatment was continued.
Otherwise, the same approach described in visit
1 was followed. Eyes failing to reach a 20% IOP
decrease from baseline under dorzolamide
monotherapy were considered
‘‘non-responders’’, and treated at the
physician’s discretion. The treatment
flow-chart is depicted in Fig. 1.
The following visits were scheduled
approximately every 60 days in the first year,
every 90 days in the second year and every
120 days in the third year. The same algorithm,
described above, for the allocation of patients in
drug groups was followed in the following
visits. The study treatment continued for
3 years or until treatment failure, whichever
occurred first. If the patient was still in
treatment at 3 years, a final visit was
performed and the study was considered
concluded.
Endpoints
The primary efficacy endpoint, calculated on a
per-eye basis, was the percentage of
‘‘responders’’, defined as eyes with IOP
reduction of at least 20% with respect to
baseline. Secondary efficacy endpoint was the
time to treatment failure, calculated as the time
from the date of baseline visit to the date in
which the medical treatment was discontinued
due to failure to maintain adequate reduction of
IOP.
Safety was assessed by evaluating the
occurrence of serious and non-serious adverse
events in general, and of the following events in
particular: excessive eyelash growth
(hypertrichosis), alterations of iris color,
corneal epitheliopathy, allergic conjunctivitis
and CCT changes.
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Statistical Considerations
Statistical Methods
The per-protocol population included only
eyes without major violation of eligibility
criteria that received treatment according to
the protocol schedule. All statistical analyses
were based on the per-protocol population.
Continuous variables were described using
mean and standard deviation (SD), while
categorical variables were described by
means of frequencies and percentages of
patients/eyes. The denominator for the
percentage calculation was based on the
total number of patients/eyes in each
relevant analysis group. In all analyses, a
p value\0.05 was considered significant.
Statistical analyses were performed using the
SAS System (v.9.4).
Sample Size Estimation
The sample size calculation was based on the
primary endpoint. Using a Fleming single stage
design, according to the A’Hern approach,
setting the probability of erroneously
concluding that the ‘‘responder’’ rate is greater
than 35% at 5% (one-sided alpha = 0.05) and
the probability of correctly concluding that the
‘‘responder’’ rate is at least 50% at 80% (beta
error = 0.20), it was found necessary to include
68 eyes. The minimum number of ‘‘responder’’
eyes was set at 31 out of 68, since this result is
associated with a lower limit of the 90% exact
confidence interval (CI) of 35.2%. Since the
number of eyes excluded from the per-protocol
population was greater than expected, to
analyze the primary outcome a recalculation
of the achievable statistical power considering
the actual number of analyzable eyes is needed.
Fig. 1 Flow-chart of study treatment schedule
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RESULTS
From July 2009 to January 2014, a total of 37
patients (69 eyes) were enrolled: 20 from the
Brescia centre and 17 from the Catania centre.
Out of 69 eyes, 4 were excluded from the
per-protocol analysis because they had not
undergone surgery and 8 because they were
not treated with the study drugs. Therefore, 57
eyes of 35 patients were analyzed and are
described in this report.
Table 1 reports the participants’ general
demographic characteristics. Mean age was
4 years (SD 3.8), 62.9% were males, and the
majority of patients were Caucasian (91.4%).
Since 28 patients (80.0%) had bilateral
glaucoma but only 22 patients (62.9%) had
both eyes eligible, the total number of eyes was
57.
The mean IOP before surgery was
27.9 mmHg (range 20.0–46.0) and the CCT
had a mean value of 558 lm (SD 47; range
485–665 lm). Angle surgery had been
performed in 35 eyes and filtration surgery in
22 eyes. Goniotomy was the most frequent
surgical procedure, performed in 22 eyes
(38.6%), followed by trabeculotomy performed
in 12 eyes (22.8%). Regarding filtration surgery,
trabeculectomy and trabeculectomy plus
trabeculotomy had been performed in 12
(21.1%) and 10 (17.5%) eyes, respectively
(Table 2).
The choice of glaucoma surgical treatment
was based on disease severity and age at onset of
the disease. Patients with glaucoma at birth
and/or cloudy cornea were treated with
trabeculectomy alone or combined
trabeculectomy and trabeculotomy. Patients
Table 1 Patients demographic characteristics (n = 35)
Age (years)
Mean (SD) 4.0 (3.8)
Min–max 0.1–13.7
Sex, n (%)
Male 22 (62.9)
Female 13 (37.1)
Ethnicity, n (%)
Caucasian 32 (91.4)
African 3 (8.6)
Bilateral glaucoma, n (%) 28 (80.0)
Both eyes analyzed, n (%) 22 (62.9)
SD standard deviation, Min–max minimum–maximum
values
Table 2 Preoperative ocular characteristics (n = 57)
Preoperative values
IOP (mmHg)
Mean (SD) 27.9 (3.9)
Min–max 20.0–46.0
Vertical/horizontal corneal diameter
(mm)
Mean (SD) 13.4 (1.0)/13.5
(1.0)
Min–max 12.0–16.0/
11.5–16.0
Central corneal thickness (lm)
Mean (SD) 558 (47)
Min–max 485–665
Surgery type, n (%)
Goniotomy 22 (38.6)
Trabeculotomy 13 (22.8)
Trabeculectomy
MMC ? trabeculotomy
12 (21.1)
Trabeculectomy MMC 10 (17.5)
SD standard deviation, Min–max minimum–maximum
values
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with mild severity (onset of glaucoma after
1 month of age) and with partially cloudy
cornea were treated with goniotomy or
trabeculotomy. Age and IOP at the time of
surgery are reported in Table 3. Mean age at the
time of surgery, was 1.3 years (SD 1.5), 3.2 years
(SD 4.1), 1.5 years (SD 1.8), and less than 1 year
(mean 0.7, SD 0.7) for patients treated with
goniotomy, trabeculotomy, trabeculectomy,
and combined trabeculectomy and
trabeculotomy, respectively.
Table 4 reports disease characteristics at
baseline. IOP levels ranged from 22 to
26 mmHg with a mean value of 23.6 mmHg
(SD 1.5). Vertical and horizontal corneal
diameters ranged from 12.0 to 16.0 mm and
from 11.5 to 16.0 mm, respectively. Mean CCT
was 561 lm (SD 49; range 485–674 lm). The
preoperative and baseline mean CCT values
were not significantly different (mean
difference 3.3 lm; SD 16.0; Wilcoxon test
p value 0.186).
At baseline, the IOP was measured in the
sitting position in 11 (31.4%) patients and in
the supine position in 24 (68.6%) patients (15
under general anesthesia; 9 awake).
DISCUSSION
GIPSy is a multicenter phase II interventional
clinical trial that aims to evaluate the efficacy of
medical treatment in a selected sample of
predominantly Caucasian PPG patients
partially responsive to a single surgical
procedure. Patients with an IOP ranging from
22 to 26 mmHg after a single surgical procedure
were included in the study. This is a frequent
Table 3 Age and intra-ocular pressure at the time of surgery
Pre-operative IOP (mmHg) Age at surgery (years)
Mean (SD) Min–max Mean (SD) Min–max
Goniotomy 28.8 (4.7) 24–46 1.3 (1.5) 0.1–4.5
Trabeculotomy 27.7 (3.1) 20–32 3.2 (4.1) 0.1–10.8
Trabeculectomy MMC ? trabeculotomy 29.1 (3.3) 24–35 0.7 (0.7) 0.0–2.2
Trabeculectomy MMC 25.5 (2.3) 22–30 1.5 (1.8) 0.3–5.6
IOP intra-ocular pressure, SD standard deviation, Min–max minimum–maximum values
Table 4 Baseline ocular characteristics (n = 57)
Baseline IOP (mmHg)
Mean (SD) 23.6 (1.5)
Min–max 22–26
Vertical/horizontal corneal diameter
(mm)
Mean (SD) 13.6 (0.9)/13.7
(0.9)
Min–max 12.0–16.0/
11.5–16.0
Central corneal thickness (lm)
Mean (SD) 561 (49)
Min–max 485–674
Iris color, n (%)
Brown 26 (45.6)
Blue/gray 12 (21.1)
Dark brown 9 (15.8)
Green 6 (10.5)
Green brown 4 (7.0)
IOP intra-ocular pressure, SD standard deviation,
Min–max minimum–maximum values
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clinical condition in which the clinician tries to
reach the target IOP by means of medical
therapy. Higher levels of IOP are generally
difficult to manage just with medical therapy,
and are often treated with further surgery. Drugs
chosen for the study are commonly used as
first-line therapy for adult glaucoma [25], but
until now systematic data have not been
available on their use for the treatment of PPG.
Thus, the choice of a prostaglandin analogue and
carbonic anhydrase inhibitor was driven by the
evidenceof their efficacy in reducing IOP in adult
glaucoma [26] and of their safety (local and
systemic) [26, 27]. A goal of the current studywas
to define an effective therapeutic algorithm
when a single surgical procedure was not able
to achieve target IOP in patients affected by PPG.
The selection of the GIPSy population was
defined in order to be highly representative of
Caucasian PPG cases described in Europe. The
mean age at presentation in the current study is
comparable to that generally reported in the
literature [28–31]. Published evidence on gender
predilection of PPG are also in agreement with
our data which show a female\male ratio equal
to 1:1.7. In agreement with previously published
literature, most of our patients (80.0%) had
bilateral glaucoma [13, 30, 32, 33].
Compared to healthy adults, children with
glaucoma have been reported to have thinner
corneas [34, 35]. Themean CCT in the GIPSywas
561 lmand ranged from 485 to 674 lm. To date,
no systematic investigations on CCT have been
performed in adequately sized samples of
patients with pediatric glaucoma. In adults, the
average corneal thickness is approximately
520 lm at the center and approximately
700 lm at the periphery [36]. The CCT in
newborns was found to be greater than 580 lm
and decreased to adult values by 3 years of age
[37, 38]. Doughty et al. [39] found similar mean
CCT values in children 5–15 years of age
compared to adults older than 32 years of age.
In a confocal microscopy study, Mastropasqua
et al. [40] reported that the corneas in pediatric
glaucoma patients have abnormal features in the
Descemet membrane, stroma and endothelium.
For example, the mean stromal keratocyte
density was markedly reduced. The authors
suggested that these findings were the direct
result of corneal distention, which may explain
why children with glaucoma have thinner
corneas. Our data on CCT could be of interest
in characterizing longitudinal changes in corneal
thickness, and the eventual long-term effects of
anti-glaucoma medications.
PPG patients recruited for this study were
surgically treated according to current clinical
practice. Angle surgeries (goniotomy and
trabeculotomy) were performed in a large
percentage of cases (61.4%) [23].
The present study has limitations. First, the
sample size is not particularly large. Recruiting
adequately sized samples is an
inevitable difficulty with trials investigating
rare diseases, particularly when highly
specialized centers and strict observation of
study procedures are necessary. Second, the
majority of participants were Caucasians.
Consequently, the results of this study may
not be generalizable to other ethnic groups.
By virtue of its design and population, the
current study is representative of a clinical
scenario encountered after the first surgery for
PPG. Therefore, the results are expected to
offer clinically relevant information on the
utility of a defined pharmacological approach
in the management of children with
glaucoma.
CONCLUSION
The Glaucoma Italian Pediatric Study (GIPSy)
investigated the use of a specific therapeutic
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algorithm with latanoprost and dorzolamide in
pediatric glaucoma patients partially responsive
to surgery. This article reports the study
protocol and baseline characteristics of study
participants.
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